<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488839</url>
  </required_header>
  <id_info>
    <org_study_id>IPX056-B06-03</org_study_id>
    <secondary_id>2007-000236-16</secondary_id>
    <nct_id>NCT00488839</nct_id>
  </id_info>
  <brief_title>IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMPAX Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMPAX Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects, both good and bad, of IPX056 on
      subjects and their spasticity. This study will also determine the relationship between the
      amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine
      how long IPX056 affects spasticity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate that IPX056 reduces spasticity,
      measured by Ashworth score, in subjects with multiple sclerosis (MS). This study will also
      (1) assess the correlation between pharmacokinetic (PK) and pharmacodynamic (PD) endpoints
      (Ashworth score), and (2) quantify the duration of pharmacodynamic effects for IPX056 as well
      as marketed baclofen tablet in subjects with Multiple Sclerosis (MS) after a single dose.
      Additionally, the efficacy parameters, including Multiple Sclerosis Impact Scale (MSIS)-29,
      spasm frequency and nighttime awakening score, spasticity control, morning stiffness, and
      Global Assessment of Efficacy and Tolerability, will be assessed during open-label extension
      period. The safety of IPX056 will be monitored throughout the study.

      This study consists of 2 parts: Part I (Screening Visit &amp; Visit 1) of the study is a
      single-dose, double-blind, randomized, placebo- and active comparator-controlled, parallel
      group design containing a single 12 hour PK/PD evaluation period. Part II is an optional,
      approximately 9-week open-label extension study and will start during Visit 1, immediately
      after Visit 1 PK/PD procedures are completed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mean changes from predose (baseline) in total Ashworth scores of the four lower extremity muscle groups (hip adductors, knee flexors, knee extensors, and plantar flexors) of both lower limbs over 12 hours assessed hourly after dosing</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of effect (improvement in Ashworth Scale) for IPX056</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establishment of relationships between baclofen plasma concentration with improvement in Ashworth Scale</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056 20 mg</intervention_name>
    <description>IPX056 Extended Release capsule containing 20 mg baclofen</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Baclofen ER 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056 40 mg</intervention_name>
    <description>IPX056 Extended Release capsule containing 40 mg baclofen</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Baclofen ER 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encapsulated Baclofen 20 mg</intervention_name>
    <description>Baclofen 20mg tablet was encapsulated for blinding.</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Baclofen Tablet</intervention_name>
    <description>Placebo capsule encapsulated placebo Baclofen tablet</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056 10 mg</intervention_name>
    <description>IPX056 Extended Release capsule containing 10 mg baclofen</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Baclofen ER 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056 30 mg</intervention_name>
    <description>IPX056 Extended Release capsule containing 30 mg baclofen</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Baclofen ER 30 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPX056 35 mg</intervention_name>
    <description>IPX056 Extended Release capsule containing 35 mg baclofen</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
    <other_name>Baclofen ER 35 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IPX056 20 mg</intervention_name>
    <description>Placebo capsule for IPX056 20 mg</description>
    <arm_group_label>IPX056 40 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IPX056 40 mg</intervention_name>
    <description>Placebo capsule for IPX056 40 mg</description>
    <arm_group_label>IPX056 20 mg - OLE</arm_group_label>
    <arm_group_label>Baclofen 20 mg - OLE</arm_group_label>
    <arm_group_label>Placebo - OLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years old. If female and of childbearing potential,
             continuing to practice and willing to continue throughout the study with appropriate
             contraceptives (defined as oral, injected, or implanted contraceptives, or barrier
             contraception). The subject must agree to take every precaution to ensure that
             pregnancy will not occur during the study. Female subjects of childbearing potential
             must have a negative urine pregnancy test immediately prior to study entry.

          -  Able to understand and willing to voluntarily sign an informed consent form (ICF) and
             an Authorization to Use and Disclose Protected Health Information form (as required by
             the Health Insurance Portability and Accountability Act {HIPAA} legislation, if
             appropriate for the region) prior to the performance of any study-specific procedures.

          -  Has a negative urine drug screen at screening visit.

          -  Has Definite multiple sclerosis by Poser or McDonald Criteria.

          -  Expanded Disability Status Scale (EDSS) rating between 3.0-8.0

          -  Has a normal ECG and a blood pressure &lt;160/95 mmHg (systolic)/diastolic) at screening,
             measured in the sitting position after approximately 5 minutes of quiet rest.

          -  If the subject has a history of or presence of clinically significant peptic ulcers,
             liver disease, diabetes mellitus, hypertension or heart disease, the subject must be
             on a stable treatment regimen for a minimum of 3 months prior to Screening Visit

          -  Wiling to wash out current medication with anti-spasticity activities, including but
             not limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam,
             gabapentin, and tizanidine.

          -  Ashworth score of 2 or more for at least one of the three lower extremity muscle
             groups (hip adductor, knee flexor, knee extensor) in the most affected limb and a
             total minimum score of 6 for four muscle groups (the above three plus plantar flexor)
             on both limbs (maximum total score is 32) during screening visit and at pre-dose
             during PK/PD Visit 1.

          -  Able and willing to comply with the protocol, including availability for all scheduled
             clinic visits

        Exclusion Criteria:

          -  If female, the subject is:

               1. pregnant; or planning to become pregnant; or

               2. breastfeeding; or

               3. a woman of child-bearing potential (defined as post menarche and biologically
                  capable of becoming pregnant [i.e., not surgically sterile]) who is engaged in
                  active heterosexual relations and is not using a barrier or hormonal form of
                  birth control (i.e. oral, injected, or implanted contraceptives).

          -  History of allergic or severe intolerance to baclofen.

          -  Did not respond to previous baclofen treatment in any formulation.

          -  Treated with intrathecal baclofen within the previous 6 months prior to the Screening
             Visit.

          -  Has experienced an exacerbation of MS within 6 months prior to the Screening Visit.

          -  Symptomatic urinary tract infection (UTI) within 4 weeks prior to the Screening Visit
             and more than two (2) UTI incidents within the last 6 months.

          -  Serum creatinine level ≥ 2 x ULN (upper limit of normal reference range) at the
             Screening Visit or requires dialysis.

          -  Liver enzyme values ≥ 2 x ULN (upper limit of normal reference range) at the Screening
             Visit.

          -  Uncontrolled peptic ulcers, liver disease, diabetes mellitus, bladder sphincter
             hypertonia, hypertension or heart disease.

          -  History of seizure or epilepsy, or is currently taking an anti-convulsant for
             treatment or control of seizure.

          -  Concomitant neurologic conditions causing spasticity (e.g. stroke, cerebral palsy,
             traumatic brain injury) or rigidity (e.g. Parkinson's disease).

          -  Any medical condition, including psychiatric disease, which would interfere with the
             interpretation of the study results, the conduct of the study, or the safety of the
             subject.

          -  Currently taking antipsychotics, CNS depressants or CNS depression producing
             medications (including alcohol, sedating antihistamines, barbiturates, narcotics, and
             phenothiazines), monoamine oxidase inhibitors (MAOI, including furazolidone,
             procarbazine, selegiline, and tranylcypromine), and tricyclics.

          -  Unable or unwilling to wash out current anti-spasticity medications, including but not
             limited to baclofen, benzodiazepines, clonazepam, clonidine, dantrolene, diazepam,
             gabapentin, and/or tizanidine for Day 1, Visit 1, procedures. However, these
             medications will be allowed during open label study.

          -  Unable or unwilling to participate 12-hour PK/PD procedures during Visit 1.

          -  Treated with Botulinum Toxin Type A or B within the previous 6 months, or Phenol or
             therapeutic alcohol nerve block within 12 months prior to the Screening Visit.

          -  History of alcohol abuse or use of recreational drugs within 12 months prior to the
             Screening Visit.

          -  Has received an investigational drug or device within 30 days prior to the Screening
             Visit.

          -  Has clinically significant limitation of passive range of motion around any of the
             joints being assessed in this study.

          -  Has had major surgery within 3 months prior to Screening visit that may affect
             spasticity assessments such as abdominal surgery, back surgery, lower leg and knee
             surgeries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Hsu, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IMPAX Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoArkansas, P. A.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoArkansas, P.A.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patricia Fodor</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhardt Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Neuroscience Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurology</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Clinical Research Center 7A</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Michigan</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crozer Chester Medical Center</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhupesh Dihenia</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integra Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Center</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre, MS Clinic, SSB</name>
      <address>
        <city>Calgary</city>
        <zip>t2n 2t9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West-Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vecmilgravis Hospital, Latvian Maritime Medicine Center</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv Regional Hospital Department of Neurology</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neurosurgery Dpt., Postgraduation training faculty, Dnipropetrovsk State medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institue of Neruology, Psychiatry and Narcology of AMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of nervous system demyelization diseases of City Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odessa Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology department of Ukraine medical stomatological akademy</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya Regional Psychoneurological Hospital</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <disposition_first_submitted>September 27, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 22, 2015</disposition_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spasticity</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

